Zolbetuximab (Anti-Claudin-18.2) is a recombinant monoclonal antibody targeting Claudin-18.2 antigen. Zolbetuximab has been used for the research of gastrointestinal adenocarcinomas and pancreatic tumors.
Zolbetuximab-SAP is a bonded toxin between a biotinylated recombinant antibody to Claudin-18.2 and the secondary conjugate Streptavidin-ZAP containing the ribosome-inactivating protein, saporin.
Zolbetuximab-SAP eliminates cells expressing Claudin-18.2. All other cells are left untouched.
The following control is included for validating the specificity of the beta conjugate: Blank-Streptavidin-SAP (Cat. #IT-27B)
This product is being offered as part of our Beta Testing program. It has saporin activity confirmed, peptide sequences published/confirmed, and/or antibody binding specificity published/confirmed. It has not been characterized or reported in scientific literature. The researcher who first publishes data* will receive a $500 credit for use on ATS products.
*Data subject to review by the scientific team at ATS. See complete details here.
keywords: zolbetuximab, claudin, claudin-18.2, gastrointestinal adenocarcinoma, pancreatic tumor, pancreas, immunotoxin, streptavidin, saporin